Nuvectis Pharma Initiates Phase 1b Combination Study of NXP900 with Osimertinib for Resistant EGFR-Mutated NSCLC
核心洞察
Nuvectis Pharma has initiated a Phase 1b study evaluating NXP900 in combination with osimertinib for patients with EGFR (搜索)-mutated non-small cell lung cancer who developed resistance to osimertinib treatment.
NXP900 is an oral small molecule inhibitor targeting SRC (搜索) and YES1 (搜索) kinases, pathways known to drive resistance to EGFR (搜索) inhibitor therapy in EGFR-mutated NSCLC patients.
The combination study targets patients with unresectable, metastatic or locally advanced EGFR (搜索)-mutated NSCLC who previously responded to osimertinib but subsequently acquired resistance.
Nuvectis Pharma has launched a Phase 1b clinical trial evaluating NXP900 in combination with osimertinib (Tagrisso®) for patients with EGFR (搜索)-mutated non-small cell lung cancer (NSCLC) who have developed resistance to osimertinib therapy. The study represents the first combination trial for NXP900, an oral small molecule inhibitor targeting SRC (搜索) and YES1 (搜索) kinases.
Addressing EGFR Inhibitor Resistance
The combination study addresses a critical unmet medical need in EGFR (搜索)-mutated NSCLC treatment. Scientific literature has established that activation of the SRC (搜索)/YES1 (搜索) pathway drives resistance to EGFR inhibitor therapy in EGFR-mutated NSCLC patients. NXP900's unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway.
Osimertinib, marketed as Tagrisso® by AstraZeneca, is a third-generation EGFR (搜索) inhibitor broadly used in patients with EGFR-mutated NSCLC as a single agent or in combination with chemotherapy as first or later line therapy.
Study Design and Patient Population
The Phase 1b study will evaluate the safety and clinical activity of the NXP900-osimertinib combination in a specific patient population. Eligible patients include those with unresectable, metastatic or locally advanced EGFR (搜索)-mutated NSCLC who have been previously treated with and had a response to osimertinib in the first or second line setting, either as a single agent or in combination with chemotherapy.
Patients whose tumors harbor mutations in the EGFR (搜索) domain known to cause resistance to osimertinib, or who have other known oncogenic drivers besides EGFR mutation, are not eligible for the study.
Clinical Development Progress
The Phase 1b program was initiated following successful completion of a Phase 1a dose escalation study in patients with advanced solid tumors and a clinical drug-drug interaction study in healthy volunteers. The ongoing single agent study evaluates NXP900's safety and clinical activity in patients with specific genetic alterations selected based on their characteristics as either direct or dependent targets of NXP900.
"We are pleased to announce the initiation of the NXP900 plus osimertinib combination study, as we continue to advance the NXP900 clinical program and unlock NXP900's promising therapeutic potential," said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis.
Future Outlook
Bentsur emphasized the potential of the all-oral combination approach: "The clinical benefit and improved outcomes afforded by osimertinib to patients with EGFR (搜索)-mutated NSCLC are well known, and we believe, based on extensive medical and scientific literature and proof of concept experiments done by us and others, that a combination with NXP900 has the potential to extend these benefits in patients who acquired resistance to osimertinib."
The company anticipates 2026 will be a pivotal year with multiple data readouts from both the single agent and combination studies. Nuvectis plans to provide regular updates from the program throughout the year as the clinical development advances.